Mr Jack Scanlan

Higher Degree by Research Candidate

School of Pharmacy and Biomedical Sciences

College of Health


As a third-year laboratory-based PhD candidate in the Mass Spectrometry and Proteomics Facility, I use mass spectrometry to improve our understanding of malignant ascites in ovarian cancer. My research focuses on identifying protein biomarkers and predictive signatures within this novel biofluid, with the aim of enabling personalised treatment strategies and improving clinical decision-making.
 
My work has been published in Science Advances and the Journal of Proteome Research, including a systematic review and experimental studies exploring proteomic predictors of therapeutic response in high-grade serous ovarian cancer. I am also interested in the broader applications of proteomics in precision medicine, including how these technologies can be translated into practice through evidence-based health policy.

Date Position Institution name
2024 - ongoing Technical Officer Adelaide University

Date Institution name Country Title
2026 - 2027 The University of Sydney Australia Master of Health Policy and Planning
2024 - 2027 Adelaide University Australia Doctor of Philosophy
2022 - 2022 University of South Australia Australia Bachelor of Biomedical Research (Honours)
2019 - 2021 Flinders University Australia Bachelor of Medical Science

Date Title Institution name Country
2025 Working with Children Check Government of South Australia -

Year Citation
2026 Scanlan, J., Mittal, P., Lokman, N. A., Oehler, M. K., Hoffmann, P., & Klingler-Hoffmann, M. (2026). Toward Proteomic-Based Prediction of Ex Vivo Platinum Sensitivity in Ovarian Cancer Ascitic Cellular Aggregates: A Pilot Study.. Journal of proteome research, 25(2), 828-841.
DOI Scopus4 WoS4
2026 Dorstyn, L., Lim, Y., Scanlan, J., McLennan, E., De Bellis, D., Katschner, M., . . . Kumar, S. (2026). Caspase-2 deficiency drives pathogenic liver polyploidy and increases age-associated hepatocellular carcinoma in mice. Science Advances, 12(1), eaeb2571-1-eaeb2571-20.
DOI Scopus1 WoS1 Europe PMC1
2026 Scanlan, J., Mittal, P., Oehler, M. K., Hoffmann, P., & Hoffmann, M. K. (2026). Proteomic Studies That Predict Patients’ Responses to High-Grade Serous Ovarian Cancer Treatments: A Systematic Review. Journal of Proteome Research, 25(2), 1126-1138.
DOI Scopus3 WoS4 Europe PMC1
2026 Lau, D., Mittal, P., Scanlan, J., Donnellan, L., Klingler-Hoffmann, M., & Hoffmann, P. (2026). Tissue-resolved proteomic characterization of oat grains guided by metabolite MALDI mass spectrometry imaging. Analytical and Bioanalytical Chemistry, 418(20), 6619-6632.
DOI Scopus1 WoS1
2026 Scanlan, J., Mittal, P., Washington, J., Young, C., Antoniou, M., Kochetkova, M., . . . Klingler-Hoffmann, M. (2026). Proteomic analysis of malignant ascites and its impact on ovarian cancer spheroids. Clinical Proteomics, 23(1), 15 pages.
DOI
2026 Scanlan, J., Mittal, P., Oehler, M. K., Hoffmann, P., & Klingler-Hoffmann, M. (2026). Correction to “Proteomic Studies That Predict Patients’ Responses to High-Grade Serous Ovarian Cancer Treatments: A Systematic Review”. Journal of Proteome Research, 25(11), 6521.
DOI

Year Citation
2026 Scanlan, J., Mittal, P., Lau, D., Lokman, N., Oehler, M., Hoffmann, P., & Klingler-Hoffmann, M. (2026). A window into the unknown: novel mass spectrometry methods to profile tumour effusion proteomes for cytokine detection and chemotherapy response prediction. Poster session presented at the meeting of 53rd Clinical Oncology Society of Australia Annual Scientific Meeting.
2026 Scanlan, J., Mittal, P., Lokman, N., Oehler, M., Hoffmann, P., & Klingler-Hoffmann, M. (2026). The proteomes of ovarian cancer ascitic cellular aggregates correlate with their ex vivo platinum sensitivities: a pilot study. Poster session presented at the meeting of Quality in Postgraduate Research 2026.
2026 Mittal, P., Lokman, N., Oehler, M., Hoffmann, P., Klingler-Hoffmann, M., & Scanlan, J. (2026). The proteomes of ovarian cancer ascitic cellular aggregates correlate with their ex vivo platinum sensitivities: a pilot study. Poster session presented at the meeting of Lorne Proteomics 2026.
2026 Scanlan, J., Mittal, P., Lokman, N., Oehler, M., Hoffmann, P., & Klingler-Hoffmann, M. (2026). The proteomes of ovarian cancer ascitic cellular aggregates correlate with their ex vivo platinum sensitivities: a pilot study. Poster session presented at the meeting of Aus-oMicS 2025.
2026 Scanlan, J., Mittal, P., Lokman, N., Blencowe, A., Oehler, M., Hoffmann, P., & Klingler-Hoffmann, M. (2026). Oral: Mining the ovarian cancer ascites proteome using a nanoparticle enrichment strategy to characterise protease activity and predict treatment response. Poster session presented at the meeting of 25th Human Proteome Organization World Congress.
2026 Scanlan, J., Mittal, P., Lokman, N., Oehler, M., Hoffmann, P., & Klingler-Hoffmann, M. (2026). Lightning talk: The proteomes of ovarian cancer ascitic cellular aggregates correlate with their ex vivo platinum sensitivities: a pilot study. Poster session presented at the meeting of Lorne Proteomics 2026.

Year Citation
2026 Scanlan, J., Mittal, P., Washington, J., Young, C., Oehler, M., Hoffmann, P., & Klingler-Hoffmann, M. (2026). Ascites-Driven Modulation of Cell Phenotypes and Proteomes: Implications for Cancer Progression.
DOI

Date Role Board name Institution name Country
2025 - 2025 Member UniSA Clinical and Health Sciences Academic Unit Board University of South Australia Australia

Date Role Committee Institution Country
2025 - ongoing Member Adelaide Protein Group Adelaide Protein Group Australia

Connect With Me

External Profiles

Other Links